Steroid Mass Spectrometry for the Diagnosis of PCOS
Abstract
:1. Introduction
1.1. Which Steroids Do We Measure?
1.2. How Do We Measure Steroids?
1.3. Liquid Chromatography Tandem Mass Spectrometry
1.4. Liquid Chromatography Tandem Mass Spectrometry and Polycystic Ovary Syndrome
2. Discussion
3. Conclusions
Funding
Conflicts of Interest
References
- Legro, R.S.; Arslanian, S.A.; Ehrmann, D.A.; Hoeger, K.M.; Murad, M.H.; Pasquali, R.; Welt, C.K. Diagnosis and treatment of polycystic ovary syndrome: An Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013, 98, 4565–4592. [Google Scholar] [CrossRef]
- Martin, K.A.; Anderson, R.R.; Chang, R.J.; Ehrmann, D.A.; Lobo, R.A.; Murad, M.H.; Pugeat, M.M.; Rosenfield, R.L. Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2018, 103, 1233–1257. [Google Scholar] [CrossRef]
- Elhassan, Y.S.; Idkowiak, J.; Smith, K.; Asia, M.; Gleeson, H.; Webster, R.; Arlt, W.; O’Reilly, M.W. Causes, Patterns, and Severity of Androgen Excess in 1205 Consecutively Recruited Women. J. Clin. Endocrinol. Metab. 2018, 103, 1214–1223. [Google Scholar] [CrossRef]
- Rosenfield, R.L.; Ehrmann, D.A. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr. Rev. 2016, 37, 467–520. [Google Scholar] [CrossRef]
- Yildiz, B.O.; Azziz, R. The adrenal and polycystic ovary syndrome. Rev. Endocr. Metab. Disord. 2007, 8, 331–342. [Google Scholar] [CrossRef]
- Kumar, A.; Woods, K.S.; Bartolucci, A.A.; Azziz, R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin. Endocrinol. 2005, 62, 644–649. [Google Scholar] [CrossRef]
- Carmina, E.; Guastella, E.; Longo, R.A. Advances in the Diagnosis and Treatment of PCOS. Curr. Pharm. Des. 2016, 22, 5508–5514. [Google Scholar] [CrossRef]
- Barth, J.H.; Field, H.P.; Yasmin, E.; Balen, A.H. Defining hyperandrogenism in polycystic ovary syndrome: Measurement of testosterone and androstenedione by liquid chromatography-tandem mass spectrometry and analysis by receiver operator characteristic plots. Eur. J. Endocrinol. 2010, 162, 611–615. [Google Scholar] [CrossRef]
- Stener-Victorin, E.; Holm, G.; Labrie, F.; Nilsson, L.; Janson, P.O.; Ohlsson, C. Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J. Clin. Endocrinol. Metab. 2010, 95, 810–819. [Google Scholar] [CrossRef]
- Janse, F.; Eijkemans, M.J.; Goverde, A.J.; Lentjes, E.G.; Hoek, A.; Lambalk, C.B.; Hickey, T.E.; Fauser, B.C.; Norman, R.J. Assessment of androgen concentration in women: Liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. Eur. J. Endocrinol. 2011, 165, 925–933. [Google Scholar] [CrossRef]
- Keefe, C.C.; Goldman, M.M.; Zhang, K.; Clarke, N.; Reitz, R.E.; Welt, C.K. Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry. PLoS ONE 2014, 9, e93805. [Google Scholar] [CrossRef]
- Keevil, B.G. How do we measure hyperandrogenemia in patients with PCOS? J. Clin. Endocrinol. Metab. 2014, 99, 777–779. [Google Scholar] [CrossRef]
- O’Reilly, M.W.; Taylor, A.E.; Crabtree, N.J.; Hughes, B.A.; Capper, F.; Crowley, R.K.; Stewart, P.M.; Tomlinson, J.W.; Arlt, W. yperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: The utility of serum androstenedione. J. Clin. Endocrinol. Metab. 2014, 99, 1027–1036. [Google Scholar] [CrossRef]
- Gunness, A.; Pazderska, A.; Ahmed, M.; McGowan, A.; Phelan, N.; Boran, G.; Taylor, A.E.; O’Reilly, M.W.; Arlt, W.; Moore, K.; et al. Measurement of selected androgens using liquid chromatography-tandem mass spectrometry in reproductive-age women with Type 1 diabetes. Hum. Reprod. (Oxf. Engl.) 2018, 33, 1727–1734. [Google Scholar] [CrossRef]
- Pretorius, E.; Arlt, W.; Storbeck, K.H. A new dawn for androgens: Novel lessons from 11-oxygenated C19 steroids. Mol. Cell. Endocrinol. 2017, 441, 76–85. [Google Scholar] [CrossRef]
- Storbeck, K.H.; Bloem, L.M.; Africander, D.; Schloms, L.; Swart, P.; Swart, A.C. 11beta-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: A putative role in castration resistant prostate cancer? Mol. Cell. Endocrinol. 2013, 377, 135–146. [Google Scholar] [CrossRef]
- Carmina, E.; Stanczyk, F.Z.; Chang, L.; Miles, R.A.; Lobo, R.A. The ratio of androstenedione:11 beta-hydroxyandrostenedione is an important marker of adrenal androgen excess in women. Fertil. Steril. 1992, 58, 148–152. [Google Scholar] [CrossRef]
- Owen, E.J.; Holownia, P.; Conway, G.S.; Jacobs, H.S.; Honour, J.W. 11 beta-hydroxyandrostenedione in plasma, follicular fluid, and granulosa cells of women with normal and polycystic ovaries. Fertil. Steril. 1992, 58, 713–718. [Google Scholar] [CrossRef]
- O’Reilly, M.W.; Kempegowda, P.; Jenkinson, C.; Taylor, A.E.; Quanson, J.L.; Storbeck, K.H.; Arlt, W. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2017, 102, 840–848. [Google Scholar] [CrossRef]
- Keevil, B.G. LC-MS/MS analysis of steroids in the clinical laboratory. Clin. Biochem. 2016, 49, 989–997. [Google Scholar] [CrossRef]
- Taylor, A.E.; Keevil, B.; Huhtaniemi, I.T. Mass spectrometry and immunoassay: How to measure steroid hormones today and tomorrow. Eur. J. Endocrinol. 2015, 173, D1–D12. [Google Scholar] [CrossRef] [PubMed]
- Monaghan, P.J.; Keevil, B.G.; Stewart, P.M.; Trainer, P.J. Case for the wider adoption of mass spectrometry-based adrenal steroid testing, and beyond. J. Clin. Endocrinol. Metab. 2014, 99, 4434–4437. [Google Scholar] [CrossRef] [PubMed]
- Handelsman, D.J.; Wartofsky, L. Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J. Clin. Endocrinol. Metab. 2013, 98, 3971–3973. [Google Scholar] [CrossRef] [PubMed]
- Wierman, M.E.; Auchus, R.J.; Haisenleder, D.J.; Hall, J.E.; Handelsman, D.; Hankinson, S.; Rosner, W.; Singh, R.J.; Sluss, P.M.; Stanczyk, F.Z. Editorial: The new instructions to authors for the reporting of steroid hormone measurements. J. Clin. Endocrinol. Metab. 2014, 99, 4375. [Google Scholar] [CrossRef] [PubMed]
- Luque-Ramirez, M.; Jimenez-Mendiguchia, L.; Garcia-Cano, A.; Fernandez-Duran, E.; de Dios Rosa, V.; Nattero-Chavez, L.; Ortiz-Flores, A.E.; Escobar-Morreale, H.F. Certified testosterone immunoassays for hyperandrogenaemia. Eur. J. Clin. Investig. 2018, 48, e13029. [Google Scholar] [CrossRef] [PubMed]
- Tosi, F.; Fiers, T.; Kaufman, J.M.; Dall’Alda, M.; Moretta, R.; Giagulli, V.A.; Bonora, E.; Moghetti, P. Implications of Androgen Assay Accuracy in the Phenotyping of Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2016, 101, 610–618. [Google Scholar] [CrossRef] [PubMed]
- Bhasin, S.; Zhang, A.; Coviello, A.; Jasuja, R.; Ulloor, J.; Singh, R.; Ulloor, J.; Singh, R.; Vesper, H.; Vasan, R.S. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008, 73, 1311–1317. [Google Scholar] [CrossRef]
- Owen, L.J.; Wu, F.C.; Buttler, R.M.; Keevil, B.G. A direct assay for the routine measurement of testosterone, androstenedione, dihydrotestosterone and dehydroepiandrosterone by liquid chromatography tandem mass spectrometry. Ann. Clin. Biochem. 2016, 53 Pt 5, 580–587. [Google Scholar] [CrossRef]
- Fanelli, F.; Gambineri, A.; Belluomo, I.; Repaci, A.; Di Lallo, V.D.; Di Dalmazi, G.; Mezzullo, M.; Prontera, O.; Cuomo, G.; Zanotti, L.; et al. Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J. Clin. Endocrinol. Metab. 2013, 98, 3058–3067. [Google Scholar] [CrossRef]
- Storbeck, K.H.; Gilligan, L.; Jenkinson, C.; Baranowski, E.S.; Quanson, J.L.; Arlt, W.; Taylor, A.E. The utility of ultra-high performance supercritical fluid chromatography-tandem mass spectrometry (UHPSFC-MS/MS) for clinically relevant steroid analysis. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2018, 1085, 36–41. [Google Scholar] [CrossRef]
- Nanba, A.T.; Rege, J.; Ren, J.; Auchus, R.J.; Rainey, W.E.; Turcu, A.F. 11-Oxygenated C19 Steroids Do Not Decline with Age in Women. J. Clin. Endocrinol. Metab. 2019, 104, 2615–2622. [Google Scholar] [CrossRef] [PubMed]
- Rothman, M.S.; Carlson, N.E.; Xu, M.; Wang, C.; Swerdloff, R.; Lee, P.; Goh, V.H.; Ridgway, E.C.; Wierman, M.E. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids 2011, 76, 177–182. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Ding, M.; Di, N.; Azziz, R.; Yang, D.; Zhao, X. Close correlation between hyperandrogenism and insulin resistance in women with polycystic ovary syndrome-Based on liquid chromatography with tandem mass spectrometry measurements. J. Clin. Lab. Anal. 2019, 33, e22699. [Google Scholar] [CrossRef] [PubMed]
- Handelsman, D.J.; Teede, H.J.; Desai, R.; Norman, R.J.; Moran, L.J. Performance of mass spectrometry steroid profiling for diagnosis of polycystic ovary syndrome. Hum. Reprod. (Oxf. Engl.) 2017, 32, 418–422. [Google Scholar] [CrossRef] [PubMed]
- Pinola, P.; Piltonen, T.T.; Puurunen, J.; Vanky, E.; Sundstrom-Poromaa, I.; Stener-Victorin, E.; Ruokonen, A.; Puukka, K.; Tapanainen, J.S.; Morin-Papunen, L.C. Androgen Profile Through Life in Women with Polycystic Ovary Syndrome: A Nordic Multicenter Collaboration Study. J. Clin. Endocrinol. Metab. 2015, 100, 3400–3407. [Google Scholar] [CrossRef] [PubMed]
- Reinehr, T.; Kulle, A.; Rothermel, J.; Knop-Schmenn, C.; Lass, N.; Bosse, C.; Holterhus, P.M. Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss. Endocr. Connect. 2017, 6, 213–224. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pasquali, R.; Zanotti, L.; Fanelli, F.; Mezzullo, M.; Fazzini, A.; Morselli Labate, A.M.; Repaci, A.; Ribichini, D.; Gambineri, A. Defining Hyperandrogenism in Women with Polycystic Ovary Syndrome: A Challenging Perspective. J. Clin. Endocrinol. Metab. 2016, 101, 2013–2022. [Google Scholar] [CrossRef]
- Deng, Y.; Zhang, Y.; Li, S.; Zhou, W.; Ye, L.; Wang, L.; Tao, T.; Gu, J.; Yang, Z.; Zhao, D.; et al. Steroid hormone profiling in obese and nonobese women with polycystic ovary syndrome. Sci. Rep. 2017, 7, 14156. [Google Scholar] [CrossRef]
- Zhu, W.; Han, B.; Fan, M.; Wang, N.; Wang, H.; Zhu, H.; Qiao, J. Oxidative stress increases the 17,20-lyase-catalyzing activity of adrenal P450c17 through p38alpha in the development of hyperandrogenism. Mol. Cell. Endocrinol. 2019, 484, 25–33. [Google Scholar] [CrossRef]
- Dhayat, N.A.; Marti, N.; Kollmann, Z.; Troendle, A.; Bally, L.; Escher, G.; Grössl, M.; Ackermann, D.; Ponte, B.; Pruijm, M.; et al. Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites. PLoS ONE 2018, 13, e0203903. [Google Scholar] [CrossRef]
- Munzker, J.; Hofer, D.; Trummer, C.; Ulbing, M.; Harger, A.; Pieber, T.; Owen, L.; Keevil, B.; Brabant, G.; Lerchbaum, E.; et al. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2015, 100, 653–660. [Google Scholar] [CrossRef] [PubMed]
- Munzker, J.; Lindheim, L.; Adaway, J.; Trummer, C.; Lerchbaum, E.; Pieber, T.R.; Keevil, B.; Obermayer-Pietsch, B. High salivary testosterone-to-androstenedione ratio and adverse metabolic phenotypes in women with polycystic ovary syndrome. Clin. Endocrinol. 2017, 86, 567–575. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, T.; Matsuzaki, T.; Miyado, M.; Saito, K.; Iwasa, T.; Matsubara, Y.; Ogata, T.; Irahara, M.; Fukami, M. 11-oxygenated C19 steroids as circulating androgens in women with polycystic ovary syndrome. Endocr. J. 2018, 65, 979–990. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amiri, M.; Tehrani, F.R.; Bidhendi-Yarandi, R.; Behboudi-Gandevani, S.; Azizi, F.; Carmina, E. Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Horm. Metab. Res. 2019, 51, 22–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parikh, T.P.; Stolze, B.R.; Ozarda Ilcol, Y.; Jonklaas, J.; Welsh, K.; Masika, L.S.; Hill, M.J.; DeCherney, A.H.; Soldin, S.J. Diurnal variation of steroid hormones and reference intervals using mass spectrometric analysis. Endocr. Connect. 2018, 7, 1354–1361. [Google Scholar] [CrossRef] [PubMed]
- Eisenhofer, G.; Peitzsch, M.; Kaden, D.; Langton, K.; Pamporaki, C.; Masjkur, J.; Tsatsaronis, G.; Mangelis, A.; Williams, T.A.; Reincke, M.; et al. Reference intervals for plasma concentrations of adrenal steroids measured by LC-MS/MS: Impact of gender, age, oral contraceptives, body mass index and blood pressure status. Clin. Chim. Acta 2017, 470, 115–124. [Google Scholar] [CrossRef]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Keevil, B. Steroid Mass Spectrometry for the Diagnosis of PCOS. Med. Sci. 2019, 7, 78. https://doi.org/10.3390/medsci7070078
Keevil B. Steroid Mass Spectrometry for the Diagnosis of PCOS. Medical Sciences. 2019; 7(7):78. https://doi.org/10.3390/medsci7070078
Chicago/Turabian StyleKeevil, Brian. 2019. "Steroid Mass Spectrometry for the Diagnosis of PCOS" Medical Sciences 7, no. 7: 78. https://doi.org/10.3390/medsci7070078